Investing.com — Apnimed Inc () takes the lead as the best-performing 2026 U.S. IPO — up +65.7% from its $16.00 IPO price to $26.51, edging out Scribe Therapeutics’ +58.7% run. Both are biotech plays, signaling that life sciences remain the IPO market’s strongest launchpad this year.
2026 U.S. IPO Leaderboard
| Company | IPO Price | Current Price | Gain from IPO | IPO Date |
|---|---|---|---|---|
| Apnimed (APMD) | $16.00 | $26.51 | +65.7% | Jul 30 |
| Scribe Therapeutics () | $15.00 | $23.80 | +58.7% | Jul 23 |
| Ionic Digital () | $53.00 | $59.20 | +11.7% | Jul 28 |
| Reformation () | $15.00 | $16.13 | +7.5% | Jul 30 |
| Jersey Mike’s Subs () | $23.00 | $23.14 | +0.6% | Jul 30 |
| SK hynix () | $149.00 | $151.05 | +1.4% | Jul 10 |
| Csquare () | $21.00 | $20.29 | -3.4% | Jul 16 |
| Standard Nuclear () | $15.00 | $8.23 | -45.1% | Jul 16 |
| QumulusAI () | $31.29 | $6.04 | -80.7% | Jul 16 |
The Biotech Duo Dominating
Apnimed’s edge is notable — it’s a sleep apnea therapy developer that priced at just $16.00, hit a 52-week high of $29.15, and sits at $26.51 today with today’s gain of +3.1%. That’s a name that has held nearly all of its post-IPO pop.
Scribe Therapeutics — a CRISPR gene editing company — has shown strong momentum, up +29.6% in just the past week alone, touching a 52-week high of $25.49. The biotech is catching a fresh wave of investor interest.
The Other Side of the Ledger
Not all 2026 IPOs delivered. QumulusAI (QMLS) has been the year’s most difficult debut — down -80.7% from its IPO price of $31.29 to just $6.04. Meanwhile, Standard Nuclear (STDN) shed -45%. The most notable IPO so far this year – – is down 19.8% from its IPO price. The IPO market in 2026 has been deeply bifurcated: biotech strength at the top, speculative names declining sharply at the bottom.
Key Takeaway
The 2026 IPO class is a tale of two markets — therapeutic biotechs are rewarding early believers, while AI and nuclear plays have largely disappointed. Apnimed’s +65.7% gain from IPO price makes it the clear winner so far, though it’s still a very young public company with its full clinical story yet to unfold.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.